Summit Therapeutics Inc. (SMMT) Stock Price & Analysis

Summit Therapeutics Inc. (SMMT) fell 8.81% to USD 13.66 as of July 25, 2026 at 04:26 UTC, according to Nexqual real-time market data.

SMMT last closed at USD 14.98; the session ranged USD 13.2–14.42 on volume of 8,152,576 shares. Market capitalization is $10.90B, with a 52-week range of USD 12.55–30.98 (NGM). Source: Nexqual, July 25, 2026 at 04:26 UTC.

Key Statistics (as of July 25, 2026 at 04:26 UTC)

Technical Analysis (SMMT)

Nexqual's technical model rates SMMT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:26 UTC.

Analyst Ratings (SMMT)

Wall Street analysts rate SMMT "Buy" based on 13 analysts, with a mean price target of USD 28.68 (range USD 9.85–44.8), per Nexqual as of July 25, 2026 at 04:26 UTC.

Earnings (SMMT)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 04:26 UTC.

Financials & Fundamentals (SMMT)

Source: Nexqual, July 25, 2026 at 04:26 UTC.

Financial Health Score (SMMT)

Nexqual rates Summit Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:26 UTC.

Ownership (SMMT)

Source: Nexqual, July 25, 2026 at 04:26 UTC.

Leadership (SMMT)

Summit Therapeutics Inc. is led by Robert W. Duggan (age 80), Co-CEO & Executive Chairman, per Nexqual as of July 25, 2026 at 04:26 UTC.

Major Backers & Investors (SMMT)

Notable institutional backers of Summit Therapeutics Inc. include Baker Bros. Advisors, LP, FMR, LLC, Price (T.Rowe) Associates Inc, according to Nexqual as of July 25, 2026 at 04:26 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 04:26 UTC.

From Summit Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)

Key Strengths & Strategy (as disclosed to the SEC)

• Trade secrets and know-how can be difficult to protect; however, we take reasonable steps to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, manufacturers, and commercial partners.
• Government Regulation As a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for serious diseases, we are subject to extensive and ongoing regulation by government authorities, including regulation by the FDA under the Federal Food, Drug, and Cosmetic Act ("FDCA") and its implementing regulations, as well as by other regulatory bodies in the United States, Europe and other countries in which we operate.
• We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary and competitive position.
• These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party.

Partnerships

• On June 3, 2024, the Company entered into the Second Amendment with Akeso to expand its territories covered under the License Agreement to also include Latin America, including Mexico and all countries in Central America and South America, the Middle East and Africa.
• Furthermore, on June 3, 2024, the Company entered into an amendment to the License Agreement with Akeso to expand its territories covered under the License Agreement to also include the Latin America, Middle East and Africa regions for which Summit paid an upfront payment of $15.0 million cash in the third quarter of 2024.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:26 UTC. This page is informational and not investment advice.